<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352323</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-17-013</org_study_id>
    <nct_id>NCT03352323</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea</brief_title>
  <official_title>Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study will measure the decrease in redness on the face of rosacea subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CEA and PSA Responders</measure>
    <time_frame>Day 15</time_frame>
    <description>Proportion of patients who are considered successes on the CEA and PSA scales (known as &quot;Responders&quot;) on Day 15 hour 12 compared to pre-dose on Day 1. Both the CEA and PSA scales range from 0-4 which corresponds to none to severe.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>oxymetazoline cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline</intervention_name>
    <description>RLD</description>
    <arm_group_label>oxymetazoline cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non-lactating female, 18 years of age or older.

          2. Signed informed consent form that meets all criteria of current Food and Drug
             Administration regulations.

          3. Females of childbearing potential must not be pregnant or lactating.

          4. Females of childbearing potential must agree to the use of a reliable method of
             contraception throughout the study.

          5. Have clinical diagnosis of rosacea with persistent (non-transient) facial erythema.

          6. Have &lt; 3 inflammatory lesions on the face.

          7. Have an erythema score of 3 (moderate) or 4 (severe) for both the CEA and the PSA that
             is reflective of the overall targeted areas.

          8. Willing to minimize external factors that might trigger rosacea flare-ups (e.g., spicy
             foods, hot drinks, hot environments, prolonged sun exposure, strong winds, emotional
             stress and alcoholic beverages) during the study.

        Exclusion Criteria:

          1. Forms of rosacea that, in the opinion of the Investigator, would interfere with the
             diagnosis or assessment of study endpoints

          2. Patient has a skin condition that, in the opinion of the Investigator, would interfere
             with the diagnosis or assessment of rosacea

          3. Patients with active sunburn or excessive facial hair such as beards, sideburns,
             moustaches, etc.

          4. Patients with moderate to severe telangiectasial masses

          5. History of blood dyscrasia.

          6. Significant history or current evidence of any uncontrolled chronic or serious disease
             or medical condition that would, in the judgment of the Investigator, would put the
             subject at undue risk or compromise the study assessments.

          7. History or current evidence of Raynaud's syndrome, severe, unstable or uncontrolled
             cardiovascular disease, orthostatic hypotension, uncontrolled hypertension or
             hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, renal or
             hepatic or renal impairment, scleroderma, Sj√∂gren's syndrome, depression, or
             narrow-angle glaucoma to an extent that, in the opinion of the Investigator, would
             place the subject at undue risk.

          8. Female patients taking hormonal contraceptives or oral estrogen for less than one
             month or those that plan to change the dosage regimen during the course of the study.

          9. Previous participation in this study.

         10. Employees of the Investigator or research center or their immediate family members.

         11. Inability to understand the requirements of the study and the relative information and
             are unable or not willing to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>J&amp;S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

